Document is current
Any future updates will be listed below
-
Authors
Tsujinaka, Hiroki
Fu, Jie
Shen, Jikui
Yu, Yun
Hafiz, Zibran
Kays, Joshua
McKenzie, David http://orcid.org/0000-0002-5533-8370
Cardona, Delia
Culp, David
Peterson, Ward
Gilger, Brian C.
Crean, Christopher S.
Zhang, Jin-Zhong
Kanan, Yogita http://orcid.org/0000-0002-6814-3484
Yu, Weiling
Cleland, Jeffrey L.
Yang, Ming
Hanes, Justin
Campochiaro, Peter A. http://orcid.org/0000-0003-2531-8229
-
Funding
Funding for this research was provided by:
Research to Prevent Blindness (none)
- License Information
-
More Information
Article History
Received: 12 November 2018
Accepted: 27 December 2019
First Online: 4 February 2020
Competing interests
: J.H., J.F. and P.A.C. are founders of Graybug Vision which has a commercial interest in sunitinib microparticles, and they have equity in Graybug and receive remuneration for consultation. Johns Hopkins University has patents on which J.H. and J.F. are authors that are licensed to Graybug Vision. All of these relationships are being managed by the Johns Hopkins University conflict of interest committee. Y.Y., D.M., D.Ca., W.Y. and M.Y. are employees of Graybug Vision. J.K., W.P., J.Z.Z. and J.L.C. are former employees of Graybug Vision. The remaining authors declare no competing interests.
